Clinical trial results using fluorescently labeled antibodies (Conference Presentation)

Eben L. Rosenthal M.D.; Nynke van den Berg; Tarn Teraphongphom; Jason Warram

doi:10.1117/12.2297305

Translator Disclaimer

14 March 2018 Clinical trial results using fluorescently labeled antibodies (Conference Presentation)

Eben L. Rosenthal M.D., Nynke van den Berg, Tarn Teraphongphom, Jason Warram

Author Affiliations +

Proceedings Volume 10469, Optical Imaging, Therapeutics, and Advanced Technology in Head and Neck Surgery and Otolaryngology 2018; 104690E (2018) https://doi.org/10.1117/12.2297305
Event: SPIE BiOS, 2018, San Francisco, California, United States

Abstract

Over the past two decades, synergistic innovations in imaging technology have resulted in a revolution in which a range of biomedical applications are now benefiting from fluorescence imaging. Fluorescence imaging of lymph nodes after systemic cetuximab-IRDye800CW administration demonstrated high sensitivity and was capable of identifying additional positive nodes on deep sectioning.

Conference Presentation

Citation Download Citation

Eben L. Rosenthal M.D., Nynke van den Berg, Tarn Teraphongphom, and Jason Warram "Clinical trial results using fluorescently labeled antibodies (Conference Presentation)", Proc. SPIE 10469, Optical Imaging, Therapeutics, and Advanced Technology in Head and Neck Surgery and Otolaryngology 2018, 104690E (14 March 2018); https://doi.org/10.1117/12.2297305

ACCESS THE FULL ARTICLE